Company intelligence / Profile preview

EndoTex Interventional Systems

Cupertino, California, United States

Ownership: Private
Development stage: Other

Overview

Developed the NexStent Carotid Stent System, which received FDA approval in 2006 for treating high-risk patients with carotid artery stenosis. Studied in the CABERNET trial showing low 30-day event rates for death, stroke, or MI.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

Boston Scientific

Beyond the preview

Go deeper on EndoTex Interventional Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EndoTex Interventional Systems.

Explore the full profile